维甲酸纳米粒混悬剂预防实验性增生性玻璃体视网膜病变  

Prevention of Retinoic Acid nanosuspension on experimental proliferative vitreoretinopathy

作　　者：张晓佳[1] 梁慷[2] 卞春及[2] 夏强[1] 段磊[1] 王梓[3] 栾洁[3] 顾宁[1] 

机构地区：[1]东南大学纳米科学与技术研究中心,国家分子电子学实验室,南京210096 [2]南京医科大学第一附属医院眼科 [3]南京东南大学附属医院眼科

出　　处：《眼科研究》2005年第1期34-36,共3页Chinese Ophthalmic Research

基　　金：国家自然科学基金资助 (60371027 );江苏省计划发展委员会资助项目(7607038009)

摘　　要：　目的　探讨维甲酸纳米粒混悬剂对兔眼实验性增生性玻璃体视网膜病变 (PVR)的预防作用。 方法　新西兰白兔 20只(40眼),随机分为 2组:对照组、用药组各 20眼。行气体压迫玻璃体手术 3d后,所有兔眼玻璃体腔内注入2×105个成纤维细胞,再分别注入BSS平衡盐溶液或 17 894mg/L的维甲酸纳米粒混悬剂 0 2mL。以间接检眼镜观察玻璃体混浊情况, 4周后剖开眼球观察视网膜脱离发生情况。 结果　在术后 1、4、7、14、21、28d,对照组分别有 12、14、14、16、20、20眼发生了玻璃体增殖;用药组分别有 9、10、10、11、12、13眼发生了玻璃体增殖,有统计学意义 (P<0 05 )。第 28d病理检查对照组 20眼中 18眼(90% )发生了视网膜脱离,用药组 20眼中 4眼(20% )发生了视网膜脱离,具有统计学意义(P<0 01)。 结论　维甲酸纳米粒混悬剂能有效地预防增生性玻璃体视网膜病变的发生。Objective To evaluate the preventive effect of retinoic acid (RA) nanosuspension on proliferative vitreoretinopathy. Methods Twenty New Zealand white rabbits (40 eyes) were divided into control group (20 eyes) and RA group (20 eyes).2×10 5 fibroblast cells were intravitreously injected in all eyes for 3 days after gas compression vitrectomy. 0 2mL of BSS were intravitreously injected in control group and 0 2mL of 17 894mg/L RA for the RA group.The situation of vitreous opacity was observed by ophthalmoscope for 4 weeks,and eyeballs were dissected for the observation of morbidity of tractional retinal detachment (TRD) 4 weeks later. Results Retinovitreous proliferation was seen in12,14,14,16,20,20 eyes in the control group at the 1st,4th,7th,14th,21st and 28th day after surgery respectively and 9,10,10,11,12,13 eyes in the RA group,showing a significant statistical difference ( P <0 05).TRD was found in 18 eyes (90%) in the control group and 4 eyes(20%) in the RA group in 28 post operation days,respectively ( P <0 01). Conclusion RA nanosuspension can effectively inhibit the occurrence of TRD.

关 键 词：维甲酸 纳米混悬剂 增生性玻璃体视网膜病变 

分 类 号：R96[医药卫生—药理学]